Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study-Reference-Cited by-同舟云学术

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Published:2016-01 Issue:1 Volume:17 Page:27-38
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Dimopoulos Meletios A,Moreau Philippe,Palumbo Antonio,Joshua Douglas,Pour Ludek,Hájek Roman,Facon Thierry,Ludwig Heinz,Oriol Albert,Goldschmidt Hartmut,Rosiñol Laura,Straub Jan,Suvorov Aleksandr,Araujo Carla,Rimashevskaya Elena,Pika Tomas,Gaidano Gianluca,Weisel Katja,Goranova-Marinova Vesselina,Schwarer Anthony,Minuk Leonard,Masszi Tamás,Karamanesht Ievgenii,Offidani Massimo,Hungria Vania,Spencer Andrew,Orlowski Robert Z,Gillenwater Heidi H,Mohamed Nehal,Feng Shibao,Chng Wee-Joo

Publisher

Elsevier BV

Subject

Oncology

Reference23 articles.

1. Cancer statistics, 2014;Siegel;CA Cancer J Clin,2014

2. Improved survival in multiple myeloma and the impact of novel therapies;Kumar;Blood,2008

3. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma;Richardson;N Engl J Med,2005

4. A phase 2 study of bortezomib in relapsed, refractory myeloma;Richardson;N Engl J Med,2003

5. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study;Moreau;Lancet Oncol,2011

Cited by 742 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiac Complications of Multiple Myeloma Treatments;Cardiology in Review;2024-09-10

2. Treatment of Early Relapse: Non-CAR T Cells;Clinical Lymphoma Myeloma and Leukemia;2024-09

3. Cancer and Heart Failure: Dangerous Liaisons;Journal of Cardiovascular Development and Disease;2024-08-27

4. Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry;PLOS ONE;2024-08-27

5. Safety of proteasome inhibitor drugs for the treatment of multiple myeloma post-marketing: a pharmacovigilance investigation based on the FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-08-19